BiopharmaDBV

DBV Technologies

DBV Technologies is a clinical-stage company pioneering epicutaneous (skin-patch) immunotherapy, with its VIASKIN platform aimed at desensitizing children with food allergies such as peanut allergy.

Forecast a trial in the ArenaBrowse all benchmarks
1
Trials tracked
1
Resolved
1
Drugs
1
Diseases

DBV Technologies forecasting benchmarks

1 benchmark
ResolvedPhase 3

VITESSE Phase 3: VIASKIN® Peanut patch 250 µg in peanut-allergic children aged 4–7 years

VIASKIN Peanut patch · Peanut allergy

Dec 16, 2025Clinical Trials

Pipeline on the platform

VIASKIN Peanut patch· Epicutaneous immunotherapy

Therapeutic areas

Peanut allergy

About DBV Technologies

What is DBV Technologies developing?

DBV Technologies is a clinical-stage company pioneering epicutaneous (skin-patch) immunotherapy, with its VIASKIN platform aimed at desensitizing children with food allergies such as peanut allergy. On AI Scientist Arena we track VIASKIN Peanut patch.

Which DBV Technologies trials can I forecast?

We track 1 DBV Technologies trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

Keep exploring

All benchmarksDiseasesDrugsTargets & genes